# GT Healthcare Capital Partners

> GT Healthcare Capital Partners is a VC fund backing Health Care. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 24
- Last investment: Jul 2024
- Lead investor: 21%
- Last updated: Aug 2026
- Website: http://www.gthcap.com/

GT Healthcare Capital Partners (“GT Healthcare”) is an Asia-based private investment partnership that specializes in healthcare investments around the globe that aim to change technology landscapes. GT Healthcare intends to provide capital and scale expertise to healthcare businesses in Asia / Greater China.

## Contacts

5 contacts available for GT Healthcare Capital Partners. Shizune tracks 4 team members at GT Healthcare Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/gt-healthcare-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 42% |
| Biotechnology | 9 | 38% |
| Medical Device | 5 | 21% |
| Medical | 4 | 17% |
| Therapeutics | 4 | 17% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 25% |
| Series C | 4 | 17% |
| Funding Round | 4 | 17% |
| Series B | 3 | 13% |
| Seed | 2 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 25% |
| United Kingdom | 5 | 21% |
| China | 1 | 4% |
| France | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alan Au | Founder / Managing Partner | 6 | https://shizune.co/investors/profile/alan-au |
| Jai Hyun Kwon | Venture Partner | 0 | https://shizune.co/investors/profile/jai-hyun-kwon |
| Jason Yeung | Partner | 0 | https://shizune.co/investors/profile/jason-yeung |
| Mingxi Li | Partner | 1 | https://shizune.co/investors/profile/mingxi-li |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Autobahn Therapeutics | Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $100M | Series C | Jul 24, 2024 |  |
| Moon Surgical | MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $55.4M | Series B | May 17, 2023 |  |
| Autobahn Therapeutics | Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $32.7M | Venture - Series Unknown | Sep 08, 2022 |  |
| Moon Surgical | MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $31.3M | Series A | Jun 07, 2022 |  |
| Boundless Bio | Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $105M | Series B | Apr 28, 2021 |  |
| Exscientia | Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize thepharmaceutical industry. | $225M | Series D | Apr 20, 2021 |  |
| Exscientia | Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize thepharmaceutical industry. | $40M | Series C | Mar 04, 2021 |  |
| G.I. Windows | G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $16.4M | Series A | Aug 19, 2020 |  |
| Exscientia | Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize thepharmaceutical industry. | $60M | Series C | May 26, 2020 |  |
| Oxford VR | Oxford VR is a spin out from Oxford University built on the work of Professor Daniel Freeman who has been developing effective VR-based mental health treatments for 15 years. Ground-breaking research, combined with the advent of highly immersive consumer VR, means that we can provide to millions treatments that are: faster and more effective thantraditional treatments; significantly lower cost to health providers; loved by users. Our focus is on developing clinically validated, cost-effective, user-centred treatments for clinical conditions with significant impact on patients, the health system and wider economy. | $13M | Series A | Feb 12, 2020 |  |

10 of 24 investments shown.

## Co-investors
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation) — VC Fund, 6 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 6 deals together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 5 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 4 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-science-enterprises) — VC Fund, 4 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Life Science Investors in United Kingdom](https://shizune.co/investors/life-science-investors-united-kingdom)
- [Life Science VC Funds in United Kingdom](https://shizune.co/investors/life-science-vc-funds-united-kingdom)

## FAQ

### What does GT Healthcare Capital Partners invest in?

GT Healthcare Capital Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series C stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact GT Healthcare Capital Partners?

Public channels for GT Healthcare Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at GT Healthcare Capital Partners?

The team at GT Healthcare Capital Partners includes Alan Au (Founder / Managing Partner), Jai Hyun Kwon (Venture Partner) and Jason Yeung (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co